Australia markets open in 8 hours

Alexion Pharmaceuticals, Inc. (ALXN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
155.01+0.54 (+0.35%)
At close: 4:00PM EDT

Alexion Pharmaceuticals, Inc.

121 Seaport Boulevard
Boston, MA 02210
United States
475 230 2596
http://www.alexion.com

Sector(s):Β Healthcare
Industry:Β Biotechnology
Full-time employees:Β 3,837

Key executives

NameTitlePayExercisedYear born
Dr. Ludwig N. HantsonCEO & Director4.25MN/A1963
Dr. Aradhana Sarin M.D.Exec. VP & CFO1.75MN/A1975
Mr. Brian M. GoffExec. VP and Chief Commercial & Global Operations Officer1.76MN/A1969
Ms. Ellen V. Chiniara J.D., Esq.Exec. VP, Chief Legal Officer & Corp. Sec.1.56MN/A1959
Dr. John J. OrloffExec. VP and Head of R&D1.83MN/A1957
Mr. Daniel A. Bazarko CPAChief Accounting Officer & Sr. VPN/AN/AN/A
Mr. Christopher J. Stevo CFAHead of Investor RelationsN/AN/AN/A
Ms. Indrani M. Lall FranchiniExec. VP & Chief Compliance OfficerN/AN/A1972
Megan GoulartSr. Director of Corp. CommunicationsN/AN/AN/A
Ms. Becky LillieInterim Chief Human Experience OfficerN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

Corporate governance

Alexion Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 April 2021 is 3. The pillar scores are Audit: 4; Board: 4; Shareholder rights: 2; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.